Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Ontology highlight
ABSTRACT: An observational time and motion study in a clinical oncology setting is utilized in order to measure and compare product attributes and overall product efficiency between lanreotide and octreotide LAR.
DISEASE(S): Neuroendocrine Tumors,Gastroenteropancreatic Neuroendocrine Tumor,Pancreatic Neoplasms,Stomach Neoplasms,Intestinal Neoplasms
PROVIDER: 2233976 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA